Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction

AIMS: The DELIVER study demonstrates a significant improvement in cardiovascular death or hospitalization for heart failure among heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF).Cost‐utility of the adjunct use of dapagliflozin to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yi, Sang, Haiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375078/
https://www.ncbi.nlm.nih.gov/pubmed/37290665
http://dx.doi.org/10.1002/ehf2.14426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375078/
https://www.ncbi.nlm.nih.gov/pubmed/37290665
http://dx.doi.org/10.1002/ehf2.14426

Ejemplares similares